Citigroup Inc. purchased a new position in Principia Biopharma Inc (NASDAQ:PRNB) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,633 shares of the company’s stock, valued at approximately $45,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio bought a new position in shares of Principia Biopharma in the fourth quarter worth $41,000. Citadel Advisors LLC bought a new position in shares of Principia Biopharma in the third quarter worth $211,000. Virtus ETF Advisers LLC bought a new position in shares of Principia Biopharma in the fourth quarter worth $282,000. Point72 Asset Management L.P. bought a new position in shares of Principia Biopharma in the third quarter worth $292,000. Finally, Marshall Wace North America L.P. bought a new position in shares of Principia Biopharma in the third quarter worth $403,000. 81.91% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on PRNB. Zacks Investment Research raised shares of Principia Biopharma from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Saturday, March 23rd. Leerink Swann set a $42.00 target price on Principia Biopharma and gave the company a “buy” rating in a research note on Thursday, March 21st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Principia Biopharma has a consensus rating of “Buy” and a consensus price target of $42.00.

PRNB opened at $30.80 on Thursday. The firm has a market capitalization of $747.71 million and a P/E ratio of 54.04. Principia Biopharma Inc has a 52 week low of $22.00 and a 52 week high of $38.34.

Principia Biopharma (NASDAQ:PRNB) last released its earnings results on Tuesday, March 19th. The company reported $0.37 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.68. The firm had revenue of $26.14 million during the quarter, compared to the consensus estimate of $13.70 million. On average, equities analysts forecast that Principia Biopharma Inc will post -2.35 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/citigroup-inc-takes-position-in-principia-biopharma-inc-prnb/2953987.html.

Principia Biopharma Profile

Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.

See Also: Analyzing a company’s cash flow statement

Institutional Ownership by Quarter for Principia Biopharma (NASDAQ:PRNB)

Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.